[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371238-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371238-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","htr1d-regulates-the-pi3kakt-signaling-pathway-to-impact-hepatocellular-carcinoma-development-and-resistance-to-sorafenib","HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib","","Hepatocellular carcinoma (HCC) carries poor prognosis largely due to resistance to treatments such as sorafenib. This study evaluates the 5-hydroxytryptamine receptor 1D (HTR1D) in cancer progression via the PI3K/Akt pathway and examines whether it can serve as a prognostic marker. Using TCGA correlation and qPCR in clinical samples, along with siRNA knockdown in Huh-7 and Hep3B cells and Western blot for PI3K/Akt signaling, HTR1D was linked to proliferation, migration, invasion, and sorafenib resistance, supported by mouse and immunohistochemistry analyses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/htr1d-regulates-the-pi3kakt-signaling-pathway-to-impact-hepatocellular-carcinoma-development-and-resistance-to-sorafenib/371238/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/htr1d-regulates-the-pi3kakt-signaling-pathway-to-impact-hepatocellular-carcinoma-development-and-resistance-to-sorafenib/371238.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this study in hepatocellular carcinoma?","Question",{"text":63,"@type":64},"The study focuses on how HTR1D regulates the PI3K/Akt signaling pathway to affect HCC development and resistance to sorafenib, and whether HTR1D can predict patient prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the relationship between HTR1D and HCC assessed?",{"text":68,"@type":64},"TCGA analysis was used to explore correlation, qPCR measured HTR1D expression in clinical samples, and siRNA knockdown in Huh-7 and Hep3B cells tested HTR1D function.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence links HTR1D to sorafenib resistance and tumor aggressiveness?",{"text":72,"@type":64},"Interfering with HTR1D promoted HCC cell proliferation, migration, and drug resistance through PI3K/Akt signaling, with findings validated in a mouse model and supported by immunohistochemical results in clinical specimens.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371238,1790379150,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Zhang et al. BMC Cancer (2025) 25:185 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-13575-5](https://doi.org/10.1186/s12885-025-13575-5)  \nRESEARCH Open Access  \nHTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib  \nYingai Zhang 1,2, Yuting Zhang2,3, Shuai Zhou4, Mujeeb Ur Rehman5, Fankai Lin 1, Jianquan Zhang4* and Hailong Zhou2  \nAbstract  \nBackground Hepatocellular carcinoma (HCC) has a poor prognosis, partly due to resistance to treatments like sorafenib. The 5-hydroxytryptamine receptor 1D (HTR1D) is involved in cancer progression through the PI3K/Akt pathway, but its role in HCC is not well understood. This study investigates HTR1D’s expression, function, and potential as a prognostic marker in HCC.  \nMethods First, the correlation between HTR1D and hepatocellular carcinoma was analyzed using theTCGA database, and the expression level of HTR1D in clinical samples was detected by qPCR. Then the siRNA was transfected into Huh-7 and Hep3B cells, and the cell proliferation ability, colony formation ability, migration and invasion ability were detected with or without sorafenib. And the expression of the PI3K/Akt pathway was detected by Western Blot. Finally, the potential of HTR1D as a predictive marker for patient prognosis was evaluated by immunohistochemistry.  \nResults Analysis of TCGA data showed that methylation ofthe HTR1D gene was associated with cancer status.  \nClinical samples confirmed significant differences in HTR1D expression between HCC and adjacent tissues, with higher expression correlating with poorer patient prognosis. Interference with HTR1D gene expression demonstrated its role in promoting HCC proliferation, migration, and drug resistance through the PI3K/Akt pathway. These findings were validated in a mouse model. Immunohistochemical analysis of clinicopathological samples suggested that HTR1D could be a valuable prognostic marker for HCC.  \nConclusion HTR1D is highly expressed in hepatocellular carcinoma tissues, and it can influence hepatocellular carcinoma development and resistance to sorafenib by regulating the PI3K/Akt signaling pathway. In addition, HTR1D has potential as a prognostic indicator.  \nKeywords Hepatocellular carcinoma, HTR1D, Sorafenib resistance, PI3K/Akt  \n*Correspondence:  \nJianquan Zhang  \n[jianquanzhang@126.com](jianquanzhang@126.com)  \n1Central Laboratory, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, Hainan 570208, China 2School of Life and Health Sciences, Hainan University,  \nHaikou, Hainan 570228, China  \n3Shanxi Medical University, Taiyuan, Shanxi 030607, China 4Hepatobiliary surgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou Hainan 570208, China  \n5Algal Bioactives and Bio products Group, State Key Laboratory of Marine Resource Utilization in South China Sea, Hainan University,  \nHaikou 570228, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vec","cbCaiuOZiqnuakGO","https://ap.wps.com/l/cbCaiuOZiqnuakGO","pdf",2591603,12,"English","# Abstract\n# Background\n# Methods\n## TCGA correlation and qPCR\n## Cell and functional assays with/without sorafenib\n## Western blot and immunohistochemistry\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the main focus of this study in hepatocellular carcinoma?\",\"answer\":\"The study focuses on how HTR1D regulates the PI3K/Akt signaling pathway to affect HCC development and resistance to sorafenib, and whether HTR1D can predict patient prognosis.\"},{\"question\":\"How was the relationship between HTR1D and HCC assessed?\",\"answer\":\"TCGA analysis was used to explore correlation, qPCR measured HTR1D expression in clinical samples, and siRNA knockdown in Huh-7 and Hep3B cells tested HTR1D function.\"},{\"question\":\"What evidence links HTR1D to sorafenib resistance and tumor aggressiveness?\",\"answer\":\"Interfering with HTR1D promoted HCC cell proliferation, migration, and drug resistance through PI3K/Akt signaling, with findings validated in a mouse model and supported by immunohistochemical results in clinical specimens.\"}]","HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib | PDF",1790191591,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0da2b3ee00b769e36d9f974dc2e47067.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ed1e7404b531d2dfe449eea7851c4c6.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e2a9f188fdfb770aaff950bea636d43.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b4634d2c60b2ff883633a0c7682de5a.webp",980,1306]